Citations

Clear

52 citation(s) found for "Sriram, S".

A Genetic Risk Variant Associated With the Risk of Primary Biliary Cholangitis Is Inherited From Neanderthals
Gerussi, Alessio , Caime, Chiara , Wang, Harold, Cordell, Heather J. , Mells, George , Sandford, Richard N., Jones, David , Hirschfield, Gideon, Siminovitch, Katherine A., Gershwin, M. Eric , Juran, Brian D., Atkinson, Elizabeth J. , Cheung, Angela, Andrade, Mariza de , Baras, Aris, Lazaridis, Konstantinos N. , Asselta, Rosanna , Invernizzi, Pietro , Group, Italian PBC Genetics Study, Jones, David E , Sironi, Manuela , Sankararaman, Sriram , Sandford, Richard , Hirschfield, Gideon M. , Group, Italian PBC Genetics Study

Mayo Clinic

Liver International | September 23, 2026 | Volume: 46 | Issue: 10 | Pages: No page available

10.1111/liv.70868 | PMID 42773620 Get It

ABSTRACT Background Primary Biliary Cholangitis (PBC) is an autoimmune cholangiopathy with polygenic architecture and unknown aetiology. Evidence links Neanderthal‐derived genetic variants to autoimmune conditions; however, their contribution to PBC susceptibility remains unexplored. Objective We investigate whether archaic alleles influence PBC risk. Design Genotype data from four PBC cohorts were analysed: CANUK (4615 cases, 9233 controls), OLD IT (444 cases, 901 controls), NEW IT (255 cases, 579 controls) and MAYO (891 cases, 621 controls). Association testing with 235 592 Neanderthal Informative Markers (NIMs) was performed, adjusting for population stratification. Heritability was estimated using RHE‐mc and temporal haplotype dynamics were assessed using ancient DNA data from Europe and Asia. Results A Neanderthal‐derived variant in TNPO3 (rs12531711), previously reported by Cordell et al. showed strong association in CANUK ( p = 2.04 × 10 −26 ) and replicated across all validation cohorts. This variant functions as an eQTL, upregulating IRF5 and downregulating TNPO3 in blood. It is rare in African populations but common both in Europeans and Asians. Temporal analysis of the haplotype carrying rs12531711 revealed frequency increased substantially during the Bronze Age (5000–3000 BP), rising from 2.0% to 7.7% in Europe and 3.4% to 17.4% in Asia, before stabilizing. Despite this strong single‐variant association, the heritability explained by NIMs was not significantly different from that of non‐NIM variants. Conclusion A Neanderthal‐derived variant contributes to PBC risk and its frequency increased in the Bronze Age, possibly due to pathogen‐driven selection. Archaic introgression overall has limited influence on PBC heritability. Functional studies are needed to elucidate the role of rs12531711.
Making the operating room (OR) work: sociomaterial study of ergonomics in the OR
Mah, Alexis, Kalocsai, Csilla , Karim, Allia , Larouche, Jeremie, Hallbeck, M Susan, Cohen, Tara, Ding, Anna, Armah, Jessica, Hallet, Julie , Helman, James D., d’Empaire, Pablo Pérez , Idestrup, Chris, Dandal, Marie-Antonette, Ryzynski, Agnes, DeSousa, Susan , Sriram, Sapna, Dales, Shannon, Cohen, Tara , Hallet, Julie , Mah, Alexis , Alam, Fahad , Hallbeck, M Susar, Ryzynski, Agnes A.

Mayo Clinic

British Journal of Surgery | July 6, 2026 | Volume: 113 | Issue: 7 | Pages: No page available

10.1093/bjs/znag083 | PMID 42405509 Get It

Abstract Background Poor operating room (OR) ergonomics poses risk of injury to OR staff, worsening patient outcomes and threatening workforce wellness and sustainability. How OR staff navigate ergonomic barriers in the interdisciplinary team environment was examined in this qualitative study. Methods Semi-structured, open-ended interviews of surgeons, anaesthesiologists, and OR nurses were conducted at a single institution using a sociomaterial approach with interview-to-the-double. Transcripts were coded by two independent researchers. Themes in the data were outlined using the System Engineering Initiative for Patient Safety (SEIPS) 2.0 framework. Results Five major themes were identified. First, physical environment issues creating cognitive and physical frictions, such as tripping hazards and poor room layouts. Second, influence of social positionality, with hierarchy by role and experience and social dynamics leading to a differential capacity to adjust. Third, team collaboration, with lack of interdisciplinary work and communication and high staff turnover. Fourth, burden of self-initiated workarounds, outlining conflicts between system/organizational issues and individual solutions. Fifth, institutional support, with lack of leadership engagement. Participants suggested solutions including accommodations to foster a collaborative approach to managing discomfort in the OR and new team communication tools. Conclusion Ergonomic barriers were described within the work system of the SEIPS 2.0 framework. Social positionality and differential levels of agency, as well as lack of team collaboration and misperceptions of others’ roles, were central to ergonomic challenges. Conflicts between problems lying with the system/organization and solutions being left to individuals were also central to challenges to optimal OR ergonomics.
An evaluation of axatilimab for the treatment of chronic graft-versus-host disease
Chhabra, Saurabh, Banigallapati, Sriram, Banigallapati, Sriram

Mayo Clinic

Expert Opinion on Biological Therapy | March 19, 2026 | Volume: 26 | Issue: 3 | Pages: 231-241

10.1080/14712598.2026.2649515 | PMID 41854671 Get It

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System
Kirkwood, Amy A. , Yohannan, Binoy , Theodorakakou, Foteini , Weverling, Flores , Simone, Valeria Di , Kumar, Shaji , Petropoulos, Ιoannis , Cohen, Oliver , Stamatelopoulos, Κimon , Whelan, Carol , Venneri, Lucia , Fontana, Marianna , Mahmood, Shameem, Schwotzer, Rahel , Wechalekar, Ashutosh , Khwaja, Jahanzaib , Milani, Paolo , Yohannan, Binoy , Theodorakakou, Foteini , Weverling, Flores , Di Simone, Valeria , Kumar, Shaji K , Petropoulos, Ioannis , Mussinelli, Roberta , Oerlemans, Marish I F J , Muchtar, E , Stamatelopoulos, Kimon , Gertz, Morie A , Fontana, Marianna , Minnema, Monique C , Dispenzieri, Angela , Palladini, Giovanni , Kastritis, Efstathios , Wechalekar, Ashutosh D. , Gillmore, Julian D , Milani, Paolo , Ravichandran, Sriram , Mussinelli, Roberta , Oerlemans, Marish I.F.J. , Muchtar, Eli , Lachmann, Helen J. , Gillmore, Julian D. , Briasoulis, Αlexandros , Gertz, Morie A. , Dispenzieri, Angela , Palladini, Giovanni , Kastritis, Efstathios

Mayo Clinic

Journal of Clinical Oncology | December 7, 2025 | Volume: 44 | Issue: 4 | Pages: 311-320

10.1200/jco-25-02558 | PMID 41353737 Get It

PURPOSE Outcomes in systemic light chain (AL) amyloidosis have improved with modern therapy limiting utility of existing risk stratification models. We validate a new staging system, incorporating longitudinal strain (LS) to the biomarker-based (NT-proBNP and Troponin-T) staging system in the contemporary treatment era (2015-2024). METHODS AL International Staging System (AL-ISS) was derived from a cohort of patients with AL amyloidosis from the UK National Amyloidosis Centre (2015-2019). The model was validated in patient cohorts from Europe (Greece, Italy, the Netherlands, and Switzerland), the United States (2015-2024), and the United Kingdom (2020-2024). RESULTS In total, 2,493 patients were included (derivation, n = 573; validation n = 1,920). In a multivariable model for the derivation cohort, LS ≥ –9% and cardiac biomarkers at previously validated thresholds (NT-proBNP 332 ng/L and 8,500 ng/L and high-sensitivity troponin T ≥ 50 ng/L) were independent poor prognostic factors stratifying patients into stages I, II, IIIA, IIIB, and IIIC. In the validation cohort, the patient stages were stage I: 317 (17%), II: 782 (41%), IIIA: 551 (29%), IIIB: 174 (9%), and IIIC: 96 (5%), respectively (first-line daratumumab treated: 826; 43%). With a median follow-up of 34 months, median overall survival (OS) was not reached (NR); estimated 1-year, 2-year, and 3-year OS was 82%, 74%, and 70% respectively. The median survival for stages I to II, IIIA, IIIB, and IIIC were NR, 67, 26, and 7 months (1-year OS IIIC 53% v 68% for IIIB in the daratumumab-treated patients), respectively ( P < .001). External validation exhibited good predictive performance: 12-month calibration slope was 1.09, Harrell C 0.69, Royston D 1.19, and R 2 D 0.25. Stage IIIC independently discriminated the poorest outcome across all cohorts. CONCLUSION This defines and validates a new staging system from systemic AL amyloidosis with robust identification of an ultra-poor risk stage (IIIC) in contemporarily treated patients.
A new validated staging system for AL amyloidosis with stage IIIc defining an ultra-poor prognostic in systemic AL amyloidosis in the modern treatment era
Kirkwood, Amy A. , Yohannan, Binoy, Weverling, Flores , Simone, Valeria Di , Kumar, Shaji, Petropoulos, Ιoannis , Cohen, Oliver C. , Stamatelopoulos, Κimon , Mahmood, Shameem, Schwotzer, Rahel , Wechalekar, Ashutosh , Gillmore, Julian D , Khwaja, Jahanzaib , Milani, Paolo, Theodorakakou, Foteini , Kumar, Shaji , Ravichandran, Sriram , Mussinelli, Roberta , Cohen, Oliver , Muchtar, Eli , Gillmore, Julian D. , Briasoulis, Αlexandros , Gertz, Morie A. , Minnema, Monique C , Dispenzieri, Angela , Palladini, Giovanni , Kastritis, Efstathios , Wechalekar, Ashutosh D.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 577-577

10.1182/blood-2025-577 Get It

Abstract Background: Systemic AL amyloidosis is an incurable disorder caused by misfolded light chain fibrils. Survival is determined by the extent of cardiac involvement and response to therapy. Mayo 2012 (stage I-IV) and European modified Mayo 2004 (stage I-IIIB) prognostic scores were developed in a historic treatment era, prior to widespread bortezomib and daratumumab use. These no longer discriminate those with the poorest outcomes. We presented a new model sub-stratifying IIIB into a high risk, ‘IIIC’ group, incorporating longitudinal strain (LS) to the European modified score (IIIC: LS &gt;-9% + NT-proBNP &gt;8500ng/L + high-sensitivity troponin T [hs-TnT] &gt;50ng/L) in the bortezomib-era (2015-2019) last year (Khwaja et al, ASH 2024). Here, we present an independent external validation of the IIIC model in the modern treatment era. Methods: The ‘IIIC model’ was derived from a large real-world cohort of adults from the UK National Amyloidosis Centre (2015-2019). Performance was externally validated across Europe (Greece, Italy, Netherlands, Switzerland), USA (2015-2024) and UK (2020-2024). Survival estimates were generated from diagnosis to death or last follow-up using the Kaplan-Meier method and groups compared using Cox regression (using Stata v18). Stage IIIB and IIIC were defined as follows IIIB: LS &lt;-9%, NT-proBNP &gt;8500ng/L, hs-TnT &gt;50ng/L and IIIC: LS &gt;-9%, NT-proBNP &gt;8500ng/L, hs-TnT &gt;50ng/L, respectively. Stage I, II and IIIa were defined as previously described in the European modification of Mayo 2004 staging system. Results: 2493 patients were analysed from 2015-2024 (derivation, n=573; validation: Europe, n=374, USA n=458, UK, n=1088). In the derivation cohort, LS ≥-9% and standard cardiac biomarkers (NT-proBNP 332ng/L and 8500ng/L and hs-TnT&gt;50ng/L) were selected as independent prognostic factors in a multivariable model. In the European and UK validation cohort (n=1462), median age at diagnosis was 67 years (range 35-95) with 1014 (69%) cardiac and 869 (60%) renal involvement. Median difference in involved and uninvolved free light chain (dFLC) was 181 mg/L (range 0-24933), NT-proBNP 1911ng/L (range 42-70000), hs-TnT 45ng/L (range 3-1221) and LS -14.7% (range -3- -28). In the US cohort median NT-proBNP was 1764 (range 13-71000) and hs-TnT 44 (6-687). Applying the new model staging, the patient stages were across Europe and UK were stage I: 224 (15%), II: 627 (43%), IIIA: 396 (27%), IIIB: 139 (10%) and IIIC: 76 (5%), respectively. 592 (41%) were treated with first-line daratumumab-based regimens. In the US dataset stage I: 103 (22%), II: 176 (38%), IIIA: 131 (29%), IIIB: 48 (10%) and IIIC: 16 (3%), respectively. 234 (51%) were treated with first-line daratumumab-based regimens. At a median follow-up of 30 months (95% CI 28-32) in the European and UK validation cohort, estimated median overall survival (OS) was not reached and 2-year OS was 74% (95% CI 72-77). Median survival for stages I-II, IIIA, IIIB and IIIC were not reached (NR), 67, 31 and 10 months, respectively (p&lt;0.001). Hazard ratios for stage II, IIIA, IIIB, IIIC were 2.01 (95% CI 1.32-3.07), 3.51 (95% CI 2.31-5.35), 5.67 (95% CI 3.60-8.91) and 11.12 (95% CI 6.93-17.87), respectively (p&lt;0.001). This was confirmed in the US cohort with a median survival for respective stages were NR, NR, NR, 8 and 2 months (p&lt;0.001). External validation in the European and UK cohorts exhibited good predictive performance: 12-month calibration slope was 1.00 (95% CI 0.81-1.20, p=0.98), Harrel's C was 0.90 (95% CI 0.76-1.00), Royston's D 1.07, R2D 0.21 (95% CI 0.15-0.28). In 1462 patients with dataset available, stage IIIC discriminated the poorest outcome despite a greater proportion treated with first-line daratumumab v IIIB in the validation cohort (59% v 40%, p=0.008). 12-month OS for IIIC v IIIB was 44% (95% CI 32-55) v 69% (95% CI 60-76), specificity for 12-month OS 97% v 92% and diagnostic odds ratio 6.62 v 2.36. Conclusions: This study validates the new staging system from stage I-IIIC with robust identification of an ultra-poor prognostic group (Stage IIIC) in a contemporarily treated patient cohort. Despite novel therapies, the OS remains &lt;12 month in the IIIC group and also poor in stage IIIB with median OS 31 months compared to a median of &gt;5 years for all other stages. This staging system can be considered as a new standard of care for risk stratification of AL amyloidosis. Novel approaches are required for patients with advanced risk.
TMET-54. Rewiring of cortical glucose metabolism fuels human brain cancer growth
O’Brien, Alexandra, Bailleul, Justine , Zhou, Weihua , Xu, Jie , Lin, Angelica , Wilder-Romans, Kari , Korimerla, Navyateja , Feng, Jiane, Zhang, Li , Andren, Anthony , Tarnal, Vijay , Redic, Kimberly, Qi, Nathan , Fischer, J, Suresh, Krithika , Venneti, Sriram , Vlashi, Erina , Wahl, Daniel , Scott, Andrew J. , Mittal, Anjali , Meghdadi, Baharan , Palavalasa, Sravya , Achreja, Abhinav , Liang, Ningning , Kothari, Ayesha U. , Edwards, Donna , Wu, Zhe , Sajjakulnukit, Peter , Park, Junyoung O. , Hoeve, Johanna ten , Fischer, Joshua, Yang, Ethan , Regan, Michael S. , Stopka, Sylwia A. , Baquer, Gerard , Sarkaria, Jann N. , Lawrence, Theodore S. , Agar, Nathalie Y.R. , Lyssiotis, Costas A. , Al‐Holou, Wajd N. , Nagrath, Deepak

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v440-v441

10.1093/neuonc/noaf201.1745 Get It

Abstract The brain avidly consumes glucose to fuel neurophysiology. Cancers of the brain, such as glioblastoma (GBM), relinquish physiological integrity and gain the ability to proliferate and invade healthy tissue. How brain cancers rewire glucose utilization to drive aggressive growth remains elusive. Here, we infused 13C-labeled glucose into patients and mice with brain cancer, coupled with quantitative metabolic flux analysis, to map the fates of glucose-derived carbon in tumor vs. cortex. Through the first direct and comprehensive measurements of carbon and nitrogen labeling in both cortex and glioma tissues, we uncover profound metabolic transformations. In human cortex, glucose carbons fuel essential physiologic processes including TCA cycle oxidation and neurotransmitter synthesis. Conversely, gliomas downregulate these processes and scavenge alternative carbon sources such as amino acids from the environment, repurposing glucose-derived carbons to generate molecules needed for proliferation and invasion. Targeting this metabolic rewiring in mice through dietary amino acid modulation selectively alters GBM metabolism, slows tumor growth, and augments the efficacy of standard-of-care treatments. These findings illuminate how aggressive brain tumors exploit glucose to suppress normal physiological activity in favor of malignant expansion and offer potential therapeutic strategies to enhance treatment outcomes.
Under pressure: live observation of ergonomic challenges in the operating room
Hallet, Julie , Sohi, Raman, Sriram, Sapna, Dales, Shannon, Ding, Anna, Larouche, Jérémie , Cohen, Tara , Helman, James D., d’Empaire, Pablo Pérez , Dandal, Marie-Antonette, Kalocsai, Csilla , Ryzynski, Agnes, DeSousa, Susan , Gombay, Anna , Hallbeck, Susan, Hallbeck, M. Susan , Alam, Fahad , Norasi, Hamid , Ryzynski, Agnes A.

Mayo Clinic

British Journal of Surgery | October 1, 2025 | Volume: 112 | Issue: 8 | Pages: No page available

10.1093/bjs/znaf158 | PMID 40794621 Get It

Interdisciplinary Operating Room Ergonomics Needs and Priorities
Mah, Alexis , Larouche, Jérémie , Dandal, Marie-Antonette, Cohen, Tara , Kallocsai, Csilla, Sriram, Sapna, Helman, James D., Hallet, Julie , Hallbeck, Susan, Norasi, Hamid , Hallet, Julie , Alam, Fahad , Hallbeck, M. Susan , Sriram, Sapna

Mayo Clinic

Annals of Surgery | November 6, 2024 | Volume: 283 | Issue: 5 | Pages: 769-775

10.1097/sla.0000000000006582 | PMID 39502068 Get It

Objective: To examine perceived operating room (OR) ergonomics facilitators and barriers, with a focus on the interdisciplinary team. Background: Poor ergonomics causes musculoskeletal injuries affecting all OR staff with repercussions on patient care, outcomes, and sustainability. Lack of ergonomic awareness and education are risk factors. Methods: We conducted a self-administered web-based survey of OR nurses, surgeons, and anesthesiologists at a single center (n = 238). We developed a questionnaire through item generation and reduction, followed by reliability and validity testing. Results: Response rate was 53.8%. Respondents perceived that on average 80% of nurses, 70% of surgeons, and 40% of anesthesiologists experienced musculoskeletal (MSK) injuries, with no difference in professional groups’ perceptions. Guideline ergonomics interventions were rarely used (<25%) except for specialized clothing (33%), equipment repositioning (59%), and seating (37%), though perceived as beneficial by 80% to 90%. Reported barriers to optimal ergonomics were organizational/structural (lack of time, space, equipment, funding), whereas solutions were individual. Fear of unfavorable perceptions from others was a concern for 62%. Teams discussing, prioritizing, monitoring, or helping with ergonomics was indicated by <50%. Individual ergonomic adaptations were perceived as convenience by other staff. Conclusions: While structural/organizational issues are reported as barriers to ergonomics, solutions appear as individual responsibilities. Team dynamics did not prioritize nor support ergonomics. Education tools leveraging the interdisciplinary team are warranted. This work will be supplemented by interviews and live observations to build tailored educational tools for OR teams.
Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial
Sise, Meghan E. , Santos, José Ramón, Goldman, Jason D. , Tuttle, Katherine R, Teixeira, J. Pedro , Seibert, A. F., Koullias, Yiannis , Llewellyn, Joe , Zhao, Yang , Hyland, Robert H. , Osinusi, Anu, Winter, Helen , Humeniuk, Rita , Hulter, Henry N., Gottlieb, Robert , Fusco, Dahlene N. , Birne, Rita , Small, Catherine B. , Plate, Markus, McPhail, Mark , Investigators, for the REDPINE, Ballesteros, Rosa , Malheiro, Luís , Silva, Gil, Correia, João Paulo , Vida, Ana Carlota, Silva, André, Carujo, Antonio, Fernandez, Jordi Carratala, Cruzado, Josep M. , Sandoval, Diego , Gimeno, Fransesc Puchades, Gómez‐Muñoz, Neus, Roma, María Martínez, Gallego, Juan Horcajada, Pablo, Castañeda, Silvia, Padilla Urrea, Sergio, Rial Crestelo, David, Santos Fernandez, Jose, Ramon, Benet, Susanna, Benítez, Rosa, Bracke, Carmen, Chamorro, Anna, Graterol, Fredzzia, Lladós, Gemma , Mateu, Lourdes , Rebollo, Boris, Romero, Alba , Soldevila, Laura , Abad, Elena, José, Alba San, Viladomiu, Alex Soriano, Abolnik, Igor Z., Acharya, Anjali , Allen, Leland, Bellovich, Keith, Burton, Mary Jane , Cameron, Miriam L., Criner, Gerard J., Criner, Lii-Yoong H, Lambert, Joseph, Rashid, Marium, Shore-Brown, Heidi, Diaz, George A., Dougherty, David W. , Erdmann, Nathaniel, Berrington, William R., Logar, Christine M., Vadivel, Nidyanandh, Everett, Allison, Lourdes, Gonzalez Suarez Maria, Berhe, Mezgebe , Colbert, Gates B. , Hebert, Christopher, Mehta, Ankit , Spak, Cedric W. , Estrada, Lorie, Vargas, Richard, Pham, Alex, Mason, Lynn, Tallmadge, Catherine, Braddom, Ariana, Nicholas, Melissa, Jamil, Aayla K. , McAllister, Ashley , Guerra, Christina, Sam, Teena , Solis, Edilia, Goyal, Munish, Laurence, Brett, Malhotra, Vinay , Manrique, Luis, McKinnell, James A., McMahon, Blaithin A. , Campbell, Ruth , Morse, Caryn G. , Navarro, Jesús, Ostrosky, Luis, Patel, Bela , Grimes, Carolyn Z. , Hernández, María , Mammadova, Mehriban, Nielsen, Laura, Umana, Virginia, Pusch, Tobias, Schrager, Harry, Mallada, Jason, Siegel, Marc , Slim, Jihad , Apodaca, Krystle D., Harkins, Michelle , Cunningham, Amy, Tuttle, Katherine R, Criner, Gerard J. , Tuttle, Katherine R. , Tuttle, Katherine R , Gottlieb, Robert L , Criner, Gerard , Teixeira, J Pedro , Tuttle, Katherine R, Regan, S. P. , Huang, Hailin , Stancampiano, Fernando F. , Libertin, Claudia R. , Investigators, for the REDPINE, Belhassen‐García, Moncef , Abelenda-Alonso, Gabriela , Rombauts, Alexander , Deltoro, Miguel García , España, Sergio, López, C. , Paredes, Roger , Viladomiu, Alex Soriano, Medjeral‐Thomas, Nicholas , Lobo, Suzana Margareth , Allen, Leland, Lambert, Joseph, Dougherty, David, Hebert, Christopher, Choe, Jennifer, McAllister, Ashley, Gotur, Deepa Bangalore , Koraishy, Farrukh M. , Malhotra, Vinay, Robinson, Philip Alan , Sanyal, Arun J. , Sriram, Peruvemba , Cunningham, Amy G, Tuttle, Katherine R

Mayo Clinic

Clinical Infectious Diseases | June 24, 2024 | Volume: 79 | Issue: 5 | Pages: 1172-1181

10.1093/cid/ciae333 | PMID 38913574 Get It

Abstract Background Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairment. Herein, the efficacy, safety, and pharmacokinetics of remdesivir, its metabolites, and sulfobutylether-β-cyclodextrin excipient were evaluated in hospitalized patients with COVID-19 and severe kidney impairment. Methods In REDPINE, a phase 3, randomized, double-blind, placebo-controlled study, participants aged ≥12 years hospitalized for COVID-19 pneumonia with acute kidney injury, chronic kidney disease, or kidney failure were randomized 2:1 to receive intravenous remdesivir (200 mg on day 1; 100 mg daily up to day 5) or placebo (enrollment from March 2021 to March 2022). The primary efficacy end point was the composite of the all-cause mortality rate or invasive mechanical ventilation rate through day 29. Safety was evaluated through day 60. Results Although enrollment concluded early, 243 participants were enrolled and treated (remdesivir, n = 163; placebo, n = 80). At baseline, 90 participants (37.0%) had acute kidney injury (remdesivir, n = 60; placebo, n = 30), 64 (26.3%) had chronic kidney disease (remdesivir, n = 44; placebo, n = 20), and 89 (36.6%) had kidney failure (remdesivir, n = 59; placebo, n = 30); and 31 (12.8%) were vaccinated against COVID-19. Composite all-cause mortality or invasive mechanical ventilation rates through day 29 were 29.4% and 32.5% in the remdesivir and placebo group, respectively (P = .61). Treatment-emergent adverse events were reported in 80.4% for remdesivir versus 77.5% for placebo, and serious adverse events in 50.3% versus 50.0%, respectively. Pharmacokinetic plasma exposure to remdesivir was not affected by kidney function. Conclusions Although the study was underpowered, no significant difference in efficacy was observed between treatment groups. REDPINE demonstrated that remdesivir is safe in patients with COVID-19 and severe kidney impairment. Clinical Trials Registration EudraCT 2020-005416-22; Clinical Trials.gov NCT04745351.
PREDICT HF: Risk stratification in advanced heart failure using novel hemodynamic parameters
Cyrille-Superville, Nicole B., Rao, Sriram , Feliberti, Jason, Swayampakala, Kamala , Snipelisky, David , Carroll, Aubrie M., Najjar, Samer S. , Belkin, Mark N. , Group, the FLIGHT Working, Grinstein, Jonathan , Patel, Priyesh Ashok , Sinha, Shashank S , Jeng, Eric I-Hun , Goswami, Rohan , Group, the FLIGHT Working

Mayo Clinic

Clinical Cardiology | June 5, 2024 | Volume: 47 | Issue: 6 | Pages: No page available

10.1002/clc.24277 | PMID 38838029 Get It

AbstractBackgroundInvasive hemodynamics are fundamental in assessing patients with advanced heart failure (HF). Several novel hemodynamic parameters have been studied; however, the relative prognostic potential remains ill‐defined.HypothesisAdvanced hemodynamic parameters provide additional prognostication beyond the standard hemodynamic assessment.MethodsPatients from the PRognostic Evaluation During Invasive CaTheterization for Heart Failure (PREDICT‐HF) registry who underwent right heart catheterization (RHC) were included in the analysis. The primary endpoint was survival to orthotopic heart transplant (OHT) or durable left ventricular assist device (LVAD), or death within 6 months of RHC.ResultsOf 846 patients included, 176 (21%) met the primary endpoint. In a multivariate model that included traditional hemodynamic variables, pulmonary capillary wedge pressure (PCWP) (OR: 1.10, 1.04−1.15, p < .001), and cardiac index (CI) (OR: 0.86, 0.81−0.92, p < .001) were shown to be predictive of adverse outcomes. In a separate multivariate model that incorporated advanced hemodynamic parameters, cardiac power output (CPO) (OR: 0.76, 0.71−0.83, p < .001), aortic pulsatility index (API) (OR: 0.94, 0.91−0.96, p < .001), and pulmonary artery pulsatility index (OR: 1.02, 1.00−1.03, p .027) were all significantly associated with the primary outcome. Positively concordant API and CPO afforded the best freedom from the endpoint (94.7%), whilst negatively concordant API and CPO had the worst freedom from the endpoint (61.5%, p < .001). Those with discordant API and CPO had similar freedom from the endpoint.ConclusionThe advanced hemodynamic parameters API and CPO are independently associated with death or the need for OHT or LVAD within 6 months. Further prospective studies are needed to validate these parameters and elucidate their role in patients with advanced HF.